Telomir Pharmaceuticals’ Successful Public Offering and Nasdaq Debut

Telomir Pharmaceuticals, Inc. (TELO) has released an update.

Telomir Pharmaceuticals, Inc. successfully conducted a public offering on February 8, 2024, underwriting 1,000,000 shares at $7.00 each, resulting in $7 million gross proceeds before expenses through Kingswood Investments. The offering, which closed on February 13, included a possible additional purchase of 150,000 shares and granted Kingswood warrants for 50,000 shares at the offering price. The deal included customary terms and a lock-up period restricting the sale of securities by insiders. Concurrently, the company’s stock, TELO, began trading on The Nasdaq Capital Market, supported by press releases about the offering’s pricing and closure.

For further insights into TELO stock, check out TipRanks’ Stock Analysis page.